Global Remicade Biosimilar Market Size, Share, Growth Analysis Report - Forecast 2034
Remicade Biosimilar Market By Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Route of Administration (Intravenous, Subcutaneous), and By Region: Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034-
Category: Healthcare Report Format : PDF
Pages: 236 Report Code: ZMR-2197
Published Date: Apr-2025 Status : Published
| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 2.82 Billion | USD 4.71 Billion | 5.4% | 2024 |
Table Of Content
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Remicade Biosimilar Market, (2022 - 2028) (USD Million)
- 2.2 Global Remicade Biosimilar Market : snapshot
- Chapter 3. Global Remicade Biosimilar Market - Industry Analysis
- 3.1 Remicade Biosimilar Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Growing demand for biosimilar drugs owing to their cost-effectiveness is likely to pave the way for market growth
- 3.3 Market Restraints
- 3.3.1. High developmental costs and complex manufacturing processes hamper the market growth
- 3.4 Market Opportunities
- 3.4.1. Major biologics patents expiration and research into new indications bring up market growth opportunities
- 3.5 Market Challenges
- 3.5.1. Significant drug-related adverse effects continue to be a market challenge
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Disease Indication
- Chapter 4. Global Remicade Biosimilar Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Remicade Biosimilar Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Remicade Biosimilar Market - Disease Indication Analysis
- 5.1 Global Remicade Biosimilar Market overview: By Disease Indication
- 5.1.1 Global Remicade Biosimilar Market share, By Disease Indication, 2021 and 2028
- 5.2 Crohn’s Disease
- 5.2.1 Global Remicade Biosimilar Market by Crohn’s Disease, 2022 - 2028 (USD Million)
- 5.3 Rheumatoid Arthritis
- 5.3.1 Global Remicade Biosimilar Market by Rheumatoid Arthritis, 2022 - 2028 (USD Million)
- 5.4 Ankylosing Spondylitis
- 5.4.1 Global Remicade Biosimilar Market by Ankylosing Spondylitis, 2022 - 2028 (USD Million)
- 5.5 Psoriatic Arthritis
- 5.5.1 Global Remicade Biosimilar Market by Psoriatic Arthritis, 2022 - 2028 (USD Million)
- 5.6 Ulcerative Colitis
- 5.6.1 Global Remicade Biosimilar Market by Ulcerative Colitis, 2022 - 2028 (USD Million)
- 5.7 Plaque Psoriasis
- 5.7.1 Global Remicade Biosimilar Market by Plaque Psoriasis, 2022 - 2028 (USD Million)
- 5.1 Global Remicade Biosimilar Market overview: By Disease Indication
- Chapter 6. Remicade Biosimilar Market - Regional Analysis
- 6.1 Global Remicade Biosimilar Market Regional Overview
- 6.2 Global Remicade Biosimilar Market Share, by Region, 2021 & 2028 (USD Million)
- 6.3. North America
- 6.3.1 North America Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.3.1.1 North America Remicade Biosimilar Market, by Country, 2022 - 2028 (USD Million)
- 6.3.1 North America Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.4 North America Remicade Biosimilar Market, by Disease Indication, 2022 - 2028
- 6.4.1 North America Remicade Biosimilar Market, by Disease Indication, 2022 - 2028 (USD Million)
- 6.4. Europe
- 6.4.2 Europe Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.4.2.1 Europe Remicade Biosimilar Market, by Country, 2022 - 2028 (USD Million)
- 6.4.2 Europe Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.4 Europe Remicade Biosimilar Market, by Disease Indication, 2022 - 2028
- 6.4.1 Europe Remicade Biosimilar Market, by Disease Indication, 2022 - 2028 (USD Million)
- 6.5. Asia Pacific
- 6.5.3 Asia Pacific Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.5.3.1 Asia Pacific Remicade Biosimilar Market, by Country, 2022 - 2028 (USD Million)
- 6.5.3 Asia Pacific Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.4 Asia Pacific Remicade Biosimilar Market, by Disease Indication, 2022 - 2028
- 6.4.1 Asia Pacific Remicade Biosimilar Market, by Disease Indication, 2022 - 2028 (USD Million)
- 6.6. Latin America
- 6.6.4 Latin America Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.6.4.1 Latin America Remicade Biosimilar Market, by Country, 2022 - 2028 (USD Million)
- 6.6.4 Latin America Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.4 Latin America Remicade Biosimilar Market, by Disease Indication, 2022 - 2028
- 6.4.1 Latin America Remicade Biosimilar Market, by Disease Indication, 2022 - 2028 (USD Million)
- 6.7. The Middle-East and Africa
- 6.7.5 The Middle-East and Africa Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.7.5.1 The Middle-East and Africa Remicade Biosimilar Market, by Country, 2022 - 2028 (USD Million)
- 6.7.5 The Middle-East and Africa Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 6.4 The Middle-East and Africa Remicade Biosimilar Market, by Disease Indication, 2022 - 2028
- 6.4.1 The Middle-East and Africa Remicade Biosimilar Market, by Disease Indication, 2022 - 2028 (USD Million)
- Chapter 7. Company Profiles
- 7.1 Johnson & Johnson
- 7.1.1 Overview
- 7.1.2 Financials
- 7.1.3 Product Portfolio
- 7.1.4 Business Strategy
- 7.1.5 Recent Developments
- 7.2 Janssen Biotech Inc
- 7.2.1 Overview
- 7.2.2 Financials
- 7.2.3 Product Portfolio
- 7.2.4 Business Strategy
- 7.2.5 Recent Developments
- 7.3 Merck & Co.
- 7.3.1 Overview
- 7.3.2 Financials
- 7.3.3 Product Portfolio
- 7.3.4 Business Strategy
- 7.3.5 Recent Developments
- 7.4 Pfizer Inc
- 7.4.1 Overview
- 7.4.2 Financials
- 7.4.3 Product Portfolio
- 7.4.4 Business Strategy
- 7.4.5 Recent Developments
- 7.5 Viatris Inc
- 7.5.1 Overview
- 7.5.2 Financials
- 7.5.3 Product Portfolio
- 7.5.4 Business Strategy
- 7.5.5 Recent Developments
- 7.6 Celltrion Inc
- 7.6.1 Overview
- 7.6.2 Financials
- 7.6.3 Product Portfolio
- 7.6.4 Business Strategy
- 7.6.5 Recent Developments
- 7.7 Alvogen
- 7.7.1 Overview
- 7.7.2 Financials
- 7.7.3 Product Portfolio
- 7.7.4 Business Strategy
- 7.7.5 Recent Developments
- 7.8 Biocon Biologics
- 7.8.1 Overview
- 7.8.2 Financials
- 7.8.3 Product Portfolio
- 7.8.4 Business Strategy
- 7.8.5 Recent Developments
- 7.9 Napp Pharmaceuticals
- 7.9.1 Overview
- 7.9.2 Financials
- 7.9.3 Product Portfolio
- 7.9.4 Business Strategy
- 7.9.5 Recent Developments
- 7.10 Nippon Kayaku
- 7.10.1 Overview
- 7.10.2 Financials
- 7.10.3 Product Portfolio
- 7.10.4 Business Strategy
- 7.10.5 Recent Developments
- 7.1 Johnson & Johnson
Table Of Figures
- 1. Market research Type
- 2. Market research methodology
- 3. Global Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 4. Porter’s Five Forces Analysis
- 5. Global Remicade Biosimilar Market attractiveness, By Disease Indication
- 6. Global Remicade Biosimilar Market share by Disease Indication, 2022 and 2028 (USD Million)
- 7. Global Remicade Biosimilar Market by Crohn’s Disease, 2022 - 2028 (USD Million)
- 8. Global Remicade Biosimilar Market by Rheumatoid Arthritis, 2022 - 2028 (USD Million)
- 9. Global Remicade Biosimilar Market by Ankylosing Spondylitis, 2022 - 2028 (USD Million)
- 10. Global Remicade Biosimilar Market by Psoriatic Arthritis, 2022 - 2028 (USD Million)
- 11. Global Remicade Biosimilar Market by Ulcerative Colitis, 2022 - 2028 (USD Million)
- 12. Global Remicade Biosimilar Market by Plaque Psoriasis, 2022 - 2028 (USD Million)
- 13. Global Remicade Biosimilar Market share, by Region, 2022 and 2028
- 14. North America Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 15. Europe Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 16. Asia Pacific Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 17. Latin America Remicade Biosimilar Market, 2022 - 2028 (USD Million)
- 18. The Middle-East and Africa Remicade Biosimilar Market, 2022 - 2028 (USD Million)
Table Of Tables
- 1. Global Remicade Biosimilar Market: Snapshot
- 2. Drivers of the Remicade Biosimilar Market: impact analysis
- 3. North America Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 4. U.S. Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 5. Canada Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 6. Europe Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 7. Germany Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 8. France Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 9. U.K. Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 10. Italy Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 11. Spain Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 12. Rest of Europe Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 13. Asia Pacific Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 14. China Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 15. Japan Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 16. India Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 17. South Korea Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 18. South-East Asia Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 19. Rest of Asia Pacific Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 20. Latin America Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 21. Brazil Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 22. Mexico Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 23. Rest of Latin America Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 24. The Middle-East and Africa Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 25. GCC Countries Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 26. South Africa Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
- 27. Rest of Middle-East Africa Remicade Biosimilar Market revenue, By Disease Indication, 2022 - 2028 (USD Million)
Methodology
FrequentlyAsked Questions
The global remicade biosimilar market is expected to grow due to rising demand for cost-effective biologic therapies, increasing prevalence of autoimmune diseases, growing approvals of biosimilars, and expanding healthcare access in emerging markets.
According to a study, the global remicade biosimilar market size was worth around USD 2.82 Billion in 2024 and is expected to reach USD 4.71 Billion by 2034.
The global remicade biosimilar market is expected to grow at a CAGR of 5.4% during the forecast period.
North America is expected to dominate the remicade biosimilar market over the forecast period.
Leading players in the global remicade biosimilar market include Johnson & Johnson, Janssen Biotech Inc, Merck & Co., Pfizer Inc, Viatris Inc, Celltrion Inc, Alvogen, Biocon Biologics, Napp Pharmaceuticals, Nippon Kayaku, among others.
The report explores crucial aspects of the remicade biosimilar market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients
